912656-34-9

Basic information

• Product Name: XEN907
• Synonyms: XEN907
• CAS NO: 912656-34-9
• Molecular Formula: C21H21NO4
• Molecular Weight: 351.39574
• Mol File: 912656-34-9.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: XEN907(CAS DataBase Reference)
• NIST Chemistry Reference: XEN907(912656-34-9)
• EPA Substance Registry System: XEN907(912656-34-9)

Safety Data

• Hazardous Substances Data: 912656-34-9(Hazardous Substances Data)

Usage

General Description

XEN907 is a novel small molecule compound that acts as a potent and selective antagonist of the Kv7.2/7.3 potassium channel. It has been shown to exhibit high potency and selectivity for the Kv7.2/7.3 channel, making it a promising candidate for the treatment of various neurological and psychiatric disorders. Preclinical studies have demonstrated its ability to reduce neuronal excitability and epileptic activity, suggesting its potential therapeutic use for conditions such as epilepsy, neuropathic pain, and mood disorders. XEN907 has shown favorable pharmacokinetic properties in animal models, making it a promising candidate for further development as a potential treatment for these disorders.

Upstream product

• 533-31-3 Sesamol 
• 912669-99-9 3-hydroxy-3-(6-hydroxy-1,3-benzodioxol-5-yl)-1-pentyl-1,3-dihydro-2H-indol-2-one 
• 4290-90-8 1-pentylisatin 
• 91-56-5 indole-2,3-dione 

Relevant articles and documents

Discovery of XEN907, a spirooxindole blocker of NaV1.7 for the treatment of pain

Starting from the oxindole 2a identified through a high-throughput screening campaign, a series of NaV1.7 blockers were developed. Following the elimination of undesirable structural features, preliminary optimization of the oxindole C-3 and N-1 substituents afforded the simplified analogue 9b, which demonstrated a 10-fold increase in target potency versus the original HTS hit. A scaffold rigidification strategy then led to the discovery of XEN907, a novel spirooxindole NaV1.7 blocker. This lead compound, which in turn showed a further 10-fold increase in potency, represents a promising structure for further optimization efforts.

SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS

This invention is directed to spiro-oxindole compounds of formula (I): wherein k, j, Q, R1, R2a, R2b, R2c, R2d, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.